TWD 30.0
(0.0%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -212.51 Million TWD | 59.09% |
2022 | -519.44 Million TWD | 26.38% |
2021 | -705.57 Million TWD | 5.33% |
2020 | -745.27 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -37.09 Million TWD | 82.55% |
2024 Q2 | 8.13 Million TWD | 121.94% |
2023 Q3 | -569.54 Million TWD | -41.48% |
2023 Q2 | -402.55 Million TWD | 18.61% |
2023 FY | -212.51 Million TWD | 59.09% |
2023 Q1 | -494.58 Million TWD | 0.0% |
2023 Q4 | -212.51 Million TWD | 62.69% |
2022 Q4 | - TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | 219.314% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | 765.642% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | 272.163% |
TTY Biopharm Company Limited | -705.97 Million TWD | 69.898% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 113.969% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 106.841% |
Center Laboratories, Inc. | 3.91 Billion TWD | 105.423% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | -269.228% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 133.54% |
InnoPharmax Inc. | -17.85 Million TWD | -1090.016% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 77.07% |
DV Biomed Co., Ltd. | 160.7 Million TWD | 232.242% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 72.804% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | 67.496% |
UniPharma Co., Ltd. | -68.36 Million TWD | -210.841% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 143.158% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | 71.206% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | -10.793% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | -10826.118% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | -680.38% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | 62.635% |